North Carolina biotech tops $400M in funding for asthma treatment
A Chapel Hill company thinks its drug has the potential to be the first oral therapy to treat patients with severe, uncontrolled asthma.
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Zac Ezzone Source Type: news